Brief: Syndax Pharmaceuticals Q3 EPS USD -84126
05/11/2024 21:01
Nov 05 (Reuters) - Syndax Pharmaceuticals Q3 operating expenses USD 102.077 million. * Q3 net income USD -84.126 million * Q3 operating income USD -89.577 million * Q3 cash & investments USD 399.6 million
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million